Kymera Therapeutics (KYMR) Current Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Current Leases for 8 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 9.11% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 9.11% YoY), while the FY2025 annual figure was $11.9 million, up 686.63% from the prior year.
• Current Leases slipped to $1.7 million in Q1 2026 per KYMR's latest filing, from $11.9 million in the prior quarter.
• Across five years, Current Leases topped out at $11.9 million in Q4 2025 and bottomed at $1.0 million in Q3 2023.
• Historically, Current Leases has averaged $3.4 million across 5 years, with a median of $1.9 million in 2025.
• On a YoY basis, Current Leases climbed as much as 686.63% in 2025 and fell as far as 83.37% in 2025.
• Kymera Therapeutics' Current Leases stood at $1.4 million in 2022, then retreated by 9.3% to $1.3 million in 2023, then gained by 18.87% to $1.5 million in 2024, then soared by 686.63% to $11.9 million in 2025, then sank by 85.75% to $1.7 million in 2026.
• Business Quant data shows KYMR's Current Leases at $1.7 million in Q1 2026, $11.9 million in Q4 2025, and $1.9 million in Q3 2025.